Scinai Immunotherapeutics Ltd. (SCNI) Stock Price & Analysis
Scinai Immunotherapeutics Ltd. (SCNI) closed at USD 0.9 on Thursday, October 15, 2026, up 2.44% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.88; the Oct 15, 2026 session ranged USD 0.76–0.94 on volume of 369,151 shares. Market capitalization is $1.22M, with a 52-week range of USD 0.75–15.5 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:10 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SCNI.md
Key facts (SCNI)
- Analysts: None.
- Total return with dividends: 1Y -93.8% vs S&P 500 +18.1%; 5Y -100.0% vs S&P 500 +85.1%.
Analysts (SCNI)
Consensus None.
Total return (dividends reinvested) (SCNI)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -93.8% | -100.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -93.9% | -78.9% |
| Volatility (annualized) | 131.2% | 94.8% |
| Max drawdown | -94.2% (Oct 2025→Oct 2026) | -100.0% (Dec 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:10 UTC)
| Price | USD 0.9 |
|---|---|
| Change | ▲ 2.44% (up) |
| Previous Close | USD 0.88 |
| Open | USD 0.78 |
| Day Range | USD 0.76 – 0.94 |
| 52-Week Range | USD 0.75 – 15.5 |
| Volume | 369,151 shares |
| Market Cap | $1.22M |
| Exchange | NCM |
Technical Analysis (SCNI)
Nexqual's technical model rates SCNI "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.07 (oversold) |
| vs SMA50 | Below (USD 1.95) |
| MACD | -0.27 (negative) |
Analyst Ratings (SCNI)
Wall Street analysts rate SCNI "None", per Nexqual as of October 16, 2026 at 05:10 UTC.
| Consensus Rating | None |
|---|
Earnings (SCNI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-12-31 | USD -240 vs est -62 ▼ miss |
| 2023-09-30 | USD 80 vs est -94 ▲ beat |
| 2023-06-30 | USD -120 vs est -91 ▼ miss |
| 2023-03-31 | USD -120 vs est -73 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financials & Fundamentals (SCNI)
| Total Revenue | $1.49M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +146.00% |
| Gross Margin | -252.32% |
| Operating Margin | -466.52% |
| Profit Margin | -174.78% |
| ROE | -26.53% |
| Debt / Equity | 0.31 |
| Current Ratio | 1.56 |
| Total Cash | $2.65M |
| Total Debt | $3.58M |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financial Health Score (SCNI)
Nexqual rates Scinai Immunotherapeutics Ltd.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:10 UTC.
| Growth | Strong — Revenue +146% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $3M cash vs $4M debt |
| Cash Flow | Weak — Operating cash flow -$7M (FY ended Dec 2022, 10-K) |
| Efficiency | Critical — ROE -27%, ROA -36.2% |
Ownership (SCNI)
| Insider Ownership | +14.16% |
|---|---|
| Institutional Ownership | +3.33% |
| Shares Outstanding | 1.35M |
| Float | 488,725 |
| Short % of Float | +1.50% |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Leadership (SCNI)
Scinai Immunotherapeutics Ltd. is led by Amir Reichman M.B.A., M.Sc. (age 49), CEO & Director, per Nexqual as of October 16, 2026 at 05:10 UTC.
| CEO & Director | Amir Reichman M.B.A., M.Sc. (age 49) |
|---|---|
| Chief Financial Officer | Uri Ben-Or (age 55) |
| Chief Operating Officer | Elad Mark B.Sc., Eng. (age 42) |
Major Backers & Investors (SCNI)
Notable institutional backers of Scinai Immunotherapeutics Ltd. include Citadel, Armistice Capital, LLC, Virtu Financial LLC, according to Nexqual as of October 16, 2026 at 05:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Citadel | 0.46% |
| Armistice Capital, LLC | 0.27% |
| Virtu Financial LLC | 0.14% |
| Xtx Topco Ltd | 0.12% |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
From Scinai Immunotherapeutics Ltd.'s Latest SEC 10-K Filing (filed 2023-04-17)
Key Strengths & Strategy (as disclosed to the SEC)
- The FDA does, however, restrict manufacturer's communications on the subject of off-label use of their products.   12     In addition, the distribution of prescription drug products, including most biological products that require a prescription, is subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:10 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt